35 results about "Amphetamine" patented technology

Described herein are silicone-containing acrylic polymers useful, for example, in transdermal drug delivery compositions, to methods of making and using them, to transdermal drug delivery compositions comprising them, and to methods of making and using such transdermal drug delivery compositions. The polymers are particular suitable for formulating amine drugs, such as amphetamine, methylphenidate, rivastigmine, paroxetine and clonidine.

Disclosed are amphetamine prodrug compositions comprising at least one non-standard amino acid conjugate of amphetamine, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.

Disclosed are novel isoflavone derivatives having the structure of Formula I

which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

It is a poison multiple and combination test agent box and its process method, which comprise plastic shell and test paper bar. The plastic shell comprises upper cover and down cover, wherein, the upper cover comprises specimen adding holes, test result display hole and fix mark hole; the down cover is set with flute. The test paper comprises test specimen area, test result display area and water absorption area, wherein, the test specimen area comprises glue gold and filter paper; the test result display area comprises pyroxylin film, C line control area with sheep and rabbit polyclonal antibody, test display area with heroin antigen and test display area with methyl amphetamine antigen. The water absorption area is set with absorption paper and fix mark.

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.

The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents and treating or preventing addictive or compulsive behavior and relapse practice of an addictive behavior or compulsion. The methods and compositions of the invention are useful in the treatment or prevention of addiction to any agent, including alcohol, nicotine, marijuana, cocaine, and amphetamines, as well as compulsive and addictive behaviors, including pathological gambling and pathological overeating.

The invention relates to an application of a lead compound namely L-corydalmine (L-CDL) of isoquinoline compounds on treating diseases related with addiction. The diseases comprise drug addiction (heroin, opium, methyl amphetamine, morphine, marihuana, cocaine, and the like), nicotine addiction, and alcohol addiction, and also comprise novel drug addiction (stimulant type novel drugs) and brain damage caused by novel drugs.

The invention provides a production method of a novel efficient rat poison which is prepared from the following raw materials in part by weight: 5-50 parts of corn meal or wheat meal or soybean meal, 10-40 parts of bran or fine bran powder, 6-36 parts of industrial paraffin at 60 DEG C, 1-30 parts of rat excrement, 1.0-10 parts of common fish meal, 0.5-10 parts of animal giblets, 0.5-5 parts of animal fat, 0.1-3.0 parts of vegetable oil, 0.01-0.5 part of table salt, 0.01-0.5 part of saccharin, 0.05-0.5 part of amphetamine, 0.001-0.25 part of warfarin or bromadiolone or brodifacoum, 0.001-0.05 part of diethyl ether, 0.001-0.1 part of nitrate or nitrite and 0.01-0.3 part of red pigment or blue pigment. The preparation comprises the steps of sequentially placing the raw materials into a container; stirring for 25-35 minutes at normal temperature under normal pressure to uniformly mix the materials; and preparing the rat poison with a feed granulator.

The present invention is directed to processes for the preparation of lisdexamfetamine and related derivatives, wherein the processes comprise coupling to racemic or enantiomerically enriched amphetamine and wherein the resulting product is advantageously enantiomerically or diastereomerically enriched in the desired stereoisomer.

The invention generally relates to hapten compounds comprising either (+)methamphetamine or (+)amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+)methamphetamine, (+)amphetamine, or (+)MDMA.

The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents where the method comprises: (a) administering to a subject a co-therapy treatment with an auricular or peri-auricular electro-acupuncture or neurostimulation device, (b) co-treatment with at least one non-narcotic detoxification agent and (c) administering to the subject an opioid antagonist. The methods and compositions of the invention are useful in the treatment or prevention of addiction to any agent, including alcohol, nicotine, marijuana, cocaine, and amphetamines, as well as compulsive and addictive behaviors, including pathological gambling and pathological overeating.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating adisease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benignprostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis/marijuana, nicotine, and activities including gambling Compounds are of general formula (I) with substituents as defined herein.

The invention relates to the technical field of biological detection, in particular to a methylamphetamine detection card for preventing urine samples from being counterfeited as well as a preparation method and application of the methylamphetamine detection card. The methylamphetamine detection card comprises a temperature sensing area, a methylamphetamine detection area and a urine property detection area, wherein the temperature sensing area is used for detecting the temperature of urine, the methylamphetamine detection area is used for detecting the content of methylamphetamine, and the urine property detection area is used for detecting the physicochemical properties of the urine; the detection card can be used for simultaneously detecting the content of methylamphetamine in a urine sample and detecting whether the urine sample is diluted or not, and has higher specificity and sensitivity on the detection of the counterfeiting of the urine sample and the detection of the content of methylamphetamine; the detection card can effectively prevent leak detection caused by the counterfeiting of the urine sample due to dilution and the like, improves the accuracy of methylamphetamine detection, and has important application value in methylamphetamine detection.

A drug-formulating method, a drug commercial-distribution method, and a drug formulation improve safety of a drug that is at risk for abuse—such as methylphenidate, or amphetamine, or an amphetamine-like central-nervous-system stimulant, and particularly a benzodiazepine. The drug is formulated into a form (not a transdermal patch) that tends to deter conversion to powder; and in this form commercially distributed—preferably enclosed in, or dissolved or dispersed into or onto, a nontoxic carrier such as a capsule, for example a gel, e.g., methylcellulose, hydroxymethylcellulose, carbomer polymer, or other gelatinous pharmaceutical agent that is FDA-acceptable. The carrier is preferably water-insoluble, to deter dissolving in water for injection, and may be an oil or a solid—for example paper or other thin medium broadly extended in two dimensions, or a sponge or other medium having generally coarse cellular structure.

The invention discloses an amphetamine immunodetection reagent and preparation and detection methods thereof. The amphetamine immunodetection reagent comprises enzyme labeled amphetamine and an indication reagent for detecting an amphetamine antibody-enzyme labeled amphetamine compound, wherein the enzyme labeled amphetamine is formed by coupling amphetamine with glucose dehydrogenase. The amphetamine immunodetection reagent can accurately and quickly determine the content of amphetamine in such samples as human blood. Compared with a conventional detection reagent on the market, the amphetamine immunodetection reagent has the advantages of being convenient and quick, high in sensitiveness, strong in specificity and accurate in quantification, and facilitates clinical popularization.

The invention discloses a deratization tracing paste and a preparation method thereof, and belongs to the field of public hygiene. The deratization tracing paste comprises 0.001-0.005% of anticoagulation powder, 0.5-5% of konjac juice, 0.05-0.5% of castor leaf juice, 5-20% of an adhesive, 0.001-0.005% of an opium poppy concentrated solution, 0.001-0.01% of amphetamine and the balance of food bait.The konjac juice and the castor leaf juice are added in the tracing paste, hairs of rats can be stimulated, thus, the rats may lick the paste and then eat the deratization tracing paste, and a deratization effect is achieved; the content of the deratization tracing paste is low, death of the rats can be delayed to prevent rats in the same nest or rat companions from discovering cause of death, resistance of the rats to the deratization tracing paste is reduced, the effect of the paste is promoted to cause nervous excitation of the rats, thus, the rats flee hither and thither to adhere the paste to the companions, and the rat kill ratio is increased.

The invention provides a method for simultaneous determination of the contents of five CYP450 probe drugs in rat plasma, and belongs to the technical field of drug interaction detection. The five probe drugs are phenacetin, amphetamine, losartan, metoprolol and midazolam respectively. The method comprises the following steps: mixing rat plasma containing phenacetin, amphetamine, losartan, metoprolol and midazolam with a diazepam solution to obtain a sample to be determined; performing UPLC-MS/MS detection on the sample to be determined to determine the contents of phenacetin, amphetamine, losartan, metoprolol and midazolam in the sample. The method has the advantages of short time and high sensitivity, and can be applied to the pharmacokinetic study of five CYP probe drugs in rats. The effects of drugs on the activities of CYP2D6, CYP1A2, CYP2B6, CYP2C9 and CYP3A4 of a cytochrome P450 enzyme subtype in rats can be studied simultaneously.